Overview Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) Status: Completed Trial end date: 2010-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM). Phase: Phase 1/Phase 2 Details Lead Sponsor: Xenon Pharmaceuticals Inc.